US Market Changes in the Treatment of Advanced Prostate Cancer


#158278

30pages

Assessment Group

$ 2900

In Stock


Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 to compare oncology practice patterns and determine trends across time in the management of advanced prostate cancer.

This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing U.S. oncologists on the treatment of patients with advanced prostate cancer.
Table of Content:

Chapter 1: Introduction 5

Chapter 2: Respondent Demographics 6

Chapter 3: Treatment of a Patient with Increased PSA and Adenocarcinoma 10

Chapter 4: Elderly Patient Treated for Gleasons 7 Adenocarcinoma, Increased PSA 18 Months Later 15

Chapter 5: Patient with Gleasons 3+4 Adenocarcinoma and Multiple Metastases to Pelvis
and Spine Develops Castration-resistant Disease 20

Chapter 6: Elderly Patient with Gleasons 5+5 and Multiple Metastases 24

Appendix A: Survey Instrument 26